Valeant Pharmaceuticals Intl (VRX) 20.27 $VRX
Valeant Pharmaceuticals, Teva, Red Hat, Schlumberger, and Southwestern Energy Company and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jun 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, TEVA, RHT, SLB and SWN.
VRX: 20.27 (-1.98), RHT: 73.62 (-4.77), TEVA: 50.01 (-1.36), SWN: 12.62 (-0.95), SLB: 76.66 (-2.93)
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
CNW Group - Fri Jun 17, 7:00AM CDT
$15 Million Investment in Steinbach, Manitoba Facility and Transfer of Xifaxan® and Apriso® Production
VRX: 20.27 (-1.98)
Follow Icahn Into Allergan Stock
Jack Foley - Amigobulls - Fri Jun 17, 5:08AM CDT
The biotech sector will recover its gains that it has lost since July 2015. Fundamentally strong Allergan will benefit handsomely.
AGN: 225.72 (-7.79), VRX: 20.27 (-1.98)
Should You Get Rid of Valeant Pharmaceuticals (VRX) Now?
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 7:31AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
VRX: 20.27 (-1.98), ORPN: 1.72 (-0.02)
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
CNW Group - Thu Jun 16, 7:00AM CDT
Inventive Eye Supplement from Bausch + Lomb Offers Consumers Greater Ease and Convenience
VRX: 20.27 (-1.98), VRX.TO: 26.36 (-1.98)
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
PR Newswire - Wed Jun 15, 7:00AM CDT
All Eleven Director Nominees Elected to the Board at Annual Meeting of Shareholders
VRX: 20.27 (-1.98), VRX.TO: 26.36 (-1.98)
Company News for June 14, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:10AM CDT
Companies in the News are: SYMC,VRX,SWHC,SAIC
SAIC: 56.67 (-1.82), VRX: 20.27 (-1.98), SWHC: 25.84 (+0.51), SYMC: 20.43 (-0.81)
Valeant's CEO Bought VRX Shares, But Here's Why You Shouldn't
Zacks Premium Research - Zacks Investment Research - Mon Jun 13, 1:39PM CDT
Joseph Papa, CEO of Valeant Pharmaceuticals, has bought close to $5 million of his company's shares. Is he bluffing though? Earnings are ultimately the key to investing, and here's how VRX's earnings expectations have been trending
VRX: 20.27 (-1.98)
Why Andrew Left and Citron Are Wrong About Facebook (FB) Stock
Ryan McQueeney - Zacks Investment Research - Mon Jun 13, 1:15PM CDT
Shares of Facebook (FB) are down about 2.5% Monday following the news that notorious short-seller Andrew Left, founder of Citron Research, was shorting shares of the social media giant. Here's why their wrong.
GPRO: 10.78 (-0.54), VRX: 20.27 (-1.98), LNKD: 190.11 (-0.34), FB: 112.08 (-3.00), MSFT: 49.83 (-2.08)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 20.27 (-1.98), AZN: 27.86 (-1.43), VRX.TO: 26.36 (-1.98)
Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-trade ideas on Lululemon, First Solar, UnitedHealth, and National Oilwell Varco or any stock you choose
PR Newswire - Thu Jun 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, LULU, FSLR, UNH and NOV.
NOV: 34.06 (-2.44), VRX: 20.27 (-1.98), FSLR: 46.02 (-2.63), UNH: 137.29 (-1.90), LULU: 69.62 (-2.20)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 37.91 (-1.72), JNJ: 115.63 (-1.75), VRX: 20.27 (-1.98), ARQL: 1.91 (-0.01)
Post-Earnings Coverage Valeant Pharma under the Microscope
ACCESSWIRE - Wed Jun 08, 8:15AM CDT
Valeant Pharmaceuticals Slumps after cutting its Forecast
PRGO: 91.01 (-4.19), VRX: 20.27 (-1.98), GILD: 80.47 (-2.90)
Apollo Global (APO) Submits Bid to Acquire Concordia
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 7:03AM CDT
Apollo Global Management, LLC (APO) has reportedly submitted a bid in the final round of Concordia Healthcare Corp. (CXRX) auction process.
VRX: 20.27 (-1.98), APO: 15.01 (-0.68), BX: 24.47 (-1.41), CXRX: 21.37 (-2.64)
Chevron and Zillow advance while Ralph Lauren skids
AP - Tue Jun 07, 4:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
VRX: 20.27 (-1.98), UNFI: 45.00 (-0.74), ALXN: 112.99 (-10.58), ZG: 34.52 (-0.98), CVX: 101.90 (-2.54), VZ: 54.43 (-0.24), RL: 89.60 (-7.65), VRX.TO: 26.36 (-1.98), Z: 34.58 (-0.80)
How to Tell if You're in a Cult Stock
David Bartosiak - Zacks Investment Research - Tue Jun 07, 4:36PM CDT
Some companies have investors that are more like cult members than share owners.
SBUX: 54.68 (-1.45), HLF: 57.50 (-4.83), TSLA: 193.15 (-3.25), VRX: 20.27 (-1.98), JPM: 59.60 (-4.45)
Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders
PR Newswire - Tue Jun 07, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders for the year ended December 31, 2015. The meeting and webcast will be held on Tuesday, June 14, 2016 at 9:00 a.m. ET at the International Headquarters, Laval Office: 2150 Saint Elzear Blvd. West, Laval Quebec, Canada H7L 4A8. Only shareholders of record at the close of business on the record date of April 20, 2016 will be entitled to vote at the meeting and any adjournments or postponements thereof.
VRX: 20.27 (-1.98), VRX.TO: 26.36 (-1.98)
Valeant Pharmaceuticals, Teva, Red Hat, Schlumberger, and Southwestern Energy Company and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jun 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, TEVA, RHT, SLB and SWN.
VRX: 20.27 (-1.98), RHT: 73.62 (-4.77), TEVA: 50.01 (-1.36), SWN: 12.62 (-0.95), SLB: 76.66 (-2.93)
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations
CNW Group - Fri Jun 17, 7:00AM CDT
$15 Million Investment in Steinbach, Manitoba Facility and Transfer of Xifaxan® and Apriso® Production
VRX: 20.27 (-1.98)
Follow Icahn Into Allergan Stock
Jack Foley - Amigobulls - Fri Jun 17, 5:08AM CDT
The biotech sector will recover its gains that it has lost since July 2015. Fundamentally strong Allergan will benefit handsomely.
AGN: 225.72 (-7.79), VRX: 20.27 (-1.98)
Should You Get Rid of Valeant Pharmaceuticals (VRX) Now?
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 7:31AM CDT
Valeant Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
VRX: 20.27 (-1.98), ORPN: 1.72 (-0.02)
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
CNW Group - Thu Jun 16, 7:00AM CDT
Inventive Eye Supplement from Bausch + Lomb Offers Consumers Greater Ease and Convenience
VRX: 20.27 (-1.98), VRX.TO: 26.36 (-1.98)
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director
PR Newswire - Wed Jun 15, 7:00AM CDT
All Eleven Director Nominees Elected to the Board at Annual Meeting of Shareholders
VRX: 20.27 (-1.98), VRX.TO: 26.36 (-1.98)
Company News for June 14, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:10AM CDT
Companies in the News are: SYMC,VRX,SWHC,SAIC
SAIC: 56.67 (-1.82), VRX: 20.27 (-1.98), SWHC: 25.84 (+0.51), SYMC: 20.43 (-0.81)
Valeant's CEO Bought VRX Shares, But Here's Why You Shouldn't
Zacks Premium Research - Zacks Investment Research - Mon Jun 13, 1:39PM CDT
Joseph Papa, CEO of Valeant Pharmaceuticals, has bought close to $5 million of his company's shares. Is he bluffing though? Earnings are ultimately the key to investing, and here's how VRX's earnings expectations have been trending
VRX: 20.27 (-1.98)
Why Andrew Left and Citron Are Wrong About Facebook (FB) Stock
Ryan McQueeney - Zacks Investment Research - Mon Jun 13, 1:15PM CDT
Shares of Facebook (FB) are down about 2.5% Monday following the news that notorious short-seller Andrew Left, founder of Citron Research, was shorting shares of the social media giant. Here's why their wrong.
GPRO: 10.78 (-0.54), VRX: 20.27 (-1.98), LNKD: 190.11 (-0.34), FB: 112.08 (-3.00), MSFT: 49.83 (-2.08)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 20.27 (-1.98), AZN: 27.86 (-1.43), VRX.TO: 26.36 (-1.98)
Learn how to target a 20% return on Valeant Pharmaceuticals, or get option-trade ideas on Lululemon, First Solar, UnitedHealth, and National Oilwell Varco or any stock you choose
PR Newswire - Thu Jun 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRX, LULU, FSLR, UNH and NOV.
NOV: 34.06 (-2.44), VRX: 20.27 (-1.98), FSLR: 46.02 (-2.63), UNH: 137.29 (-1.90), LULU: 69.62 (-2.20)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 37.91 (-1.72), JNJ: 115.63 (-1.75), VRX: 20.27 (-1.98), ARQL: 1.91 (-0.01)
Post-Earnings Coverage Valeant Pharma under the Microscope
ACCESSWIRE - Wed Jun 08, 8:15AM CDT
Valeant Pharmaceuticals Slumps after cutting its Forecast
PRGO: 91.01 (-4.19), VRX: 20.27 (-1.98), GILD: 80.47 (-2.90)
Apollo Global (APO) Submits Bid to Acquire Concordia
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 7:03AM CDT
Apollo Global Management, LLC (APO) has reportedly submitted a bid in the final round of Concordia Healthcare Corp. (CXRX) auction process.
VRX: 20.27 (-1.98), APO: 15.01 (-0.68), BX: 24.47 (-1.41), CXRX: 21.37 (-2.64)
Chevron and Zillow advance while Ralph Lauren skids
AP - Tue Jun 07, 4:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
VRX: 20.27 (-1.98), UNFI: 45.00 (-0.74), ALXN: 112.99 (-10.58), ZG: 34.52 (-0.98), CVX: 101.90 (-2.54), VZ: 54.43 (-0.24), RL: 89.60 (-7.65), VRX.TO: 26.36 (-1.98), Z: 34.58 (-0.80)
How to Tell if You're in a Cult Stock
David Bartosiak - Zacks Investment Research - Tue Jun 07, 4:36PM CDT
Some companies have investors that are more like cult members than share owners.
SBUX: 54.68 (-1.45), HLF: 57.50 (-4.83), TSLA: 193.15 (-3.25), VRX: 20.27 (-1.98), JPM: 59.60 (-4.45)
Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders
PR Newswire - Tue Jun 07, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders for the year ended December 31, 2015. The meeting and webcast will be held on Tuesday, June 14, 2016 at 9:00 a.m. ET at the International Headquarters, Laval Office: 2150 Saint Elzear Blvd. West, Laval Quebec, Canada H7L 4A8. Only shareholders of record at the close of business on the record date of April 20, 2016 will be entitled to vote at the meeting and any adjournments or postponements thereof.
VRX: 20.27 (-1.98), VRX.TO: 26.36 (-1.98)
